salesforce.com, inc. (NYSE:CRM), the biggest maker of customer-management software, forecast second-quarter sales that exceeded analysts’ predictions as the company’s Web-based products continue to lure new users. Revenue in the quarter ending in July will be about $1.29 billion, the San Francisco-based company said yesterday in a statement. salesforce.com, inc. (NYSE:CRM) stock performance was -5.10% in last session and finished the day at $50.19. Traded volume was 20,481,072 shares in the last session and the average volume of the stock remained 6.85 million shares. The beta of the stock remained 0.97. salesforce.com, inc. (NYSE:CRM) insider ownership is 0.30%.

Liquid Holdings Group Inc (NASDAQ:LIQD) slipped -5.23% after the company announced that the company has signed a joint marketing agreement with ConvergEx Prime Services LLC, the prime services division of ConvergEx Group LLC. Under the terms of the agreement, ConvergEx Prime Services will offer the Liquid platform as an option to its broad portfolio of prime brokerage clients including hedge funds, family offices, mutual funds, and registered advisors, and Liquid will refer its clients to ConvergEx for prime brokerage services. Liquid Holdings Group Inc (NASDAQ:LIQD) dropped -8.72% to $1.57 yesterday on volume of 5,914,103 shares. The intra-day range of the stock was $1.51 – 1.87. Liquid Holdings Group Inc (NASDAQ:LIQD) has a market capitalization of $89.24 million.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on May 13 announced it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer’s disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University’s Shanghai Medical College. Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s stock on May 21, 2014 reported a decrease of -6.70% to the closing price of $2.09. Its fifty two weeks range is $0.61 – 3.9. The total market capitalization recorded $502.92 million. The overall volume in the last trading session was 3,706,042 shares. In its share capital, Inovio Pharmaceuticals Inc (NYSEMKT:INO) has 240.61 million outstanding shares.

Zogenix, Inc. (NASDAQ:ZGNX) announced the closing of its previously announced sale of its SUMAVEL DosePro Needle-free Delivery System (sumatriptan injection) product line to Endo International plc (Nasdaq: ENDP) for $85 million in cash and milestone payments of up to $20 million. Roger Hawley, Chief Executive Officer of Zogenix, said, “We are pleased to complete this transaction and look forward to collaborating with Endo to ensure a smooth transition and to support the ongoing success of SUMAVEL DosePro.” On Wednesday, shares of Zogenix, Inc. (NASDAQ:ZGNX) dropped -5.37% to close the day at $1.94. Company return on investment (ROI) is -112.70% and its monthly performance is recorded as -35.55%. Zogenix, Inc. (NASDAQ:ZGNX) quarterly revenue growth is -57.92%.